USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/21200
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOală, Diana-
dc.date.accessioned2022-06-17T07:16:17Z-
dc.date.available2022-06-17T07:16:17Z-
dc.date.issued2022-
dc.identifier.citationOALĂ, Diana. Clinical features in patients with gout and metabolic syndrome. In: MedEspera: the 9th International Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2022, p.164.en_US
dc.identifier.urihttps://medespera.asr.md/en/books?page=1-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/21200-
dc.description.abstractIntroduction. In the last decades, the incidence of gout has increased in patients with metabolic syndrome. Gout associated with metabolic syndrome increases the risks of cardiovascular and renal complications. Aim of study. Evaluation of clinical features in patients with gout and metabolic syndrome. Methods and materials. A retrospective study of 120 medical records of patients diagnosed with gout (according to ACR criteria) hospitalised in the Rheumatology and Arthrology departments of the Public Medical Sanitary Institution Republican Clinical Hospital Timofei Mosneaga during 2019-2021. Results. The study included 110 men (91.6%) and 10 women (8.4%). The average age of patients is 59 years. There were 75 patients with acute gout (622.5%) and 45 patients with chronic gout (37.5%). MS was detected in 65 patients (54.2%), of whom 7 were women (10.8%) and 58 were men (89.2%). Presence of MS-associated diseases: diabetes mellitus - 27 patients (41.5%), hypertension - 62 patients (95.4%), dyslipidemia - 37 patients (56.9%), hepatic steatosis - 17 patients (26.2 %), obesity - 27 patients (41.5%), chronic heart disease - 57 patients (87.7%), kidney stones - 28 patients (43.1%), chronic pancreatitis - 49 patients (75.4%). According to the laboratory data of 120 patients: hyperuricemia was detected in 55 patients (45.8%). According to the treatment for cupping the acute process was administered colchicine - 59 patients (49.2%), anti-inflammatory nonsteroidal drugs - 45 patients (37.5%) and infiltrations in joints with glucocorticosteroid - 36 patients (30%). The long-term treatments: allopurinol - 105 patients (87.5%), febuxostat - 27 patients (22.5%). Conclusion. The development of target organs damage in patients with metabolic syndrome and gout was detected in 65 patients (54.2%), compared to patients with gout without metabolic syndrome - 55 patients (45.8%). Highlighting patients with gout, with or without metabolic syndrome, is necessary in order to establish the early target organs damage and prevent complications.en_US
dc.language.isoenen_US
dc.publisherNicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova, Association of Medical Students and Residentsen_US
dc.relation.ispartofMedEspera: The 9th International Medical Congress for Students and Young Doctors, May 12-14, 2022, Chisinau, Republic of Moldovaen_US
dc.subjectgouten_US
dc.subjectmetabolic syndromeen_US
dc.subjectfeaturesen_US
dc.subjecttarget organsen_US
dc.titleClinical features in patients with gout and metabolic syndromeen_US
dc.typeOtheren_US
Appears in Collections:MedEspera 2022

Files in This Item:
File Description SizeFormat 
CLINICAL_FEATURES_IN_PATIENTS_WITH_GOUT_AND_METABOLIC_SYNDROME.pdf218.44 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback